イベント詳細

Sustainable growth and the future outlook in the pharmaceutical market in Japan will continue to be impacted by multiple trends, including: increasing patent expiry, expanding generic competitors, new drug launches focusing on unmet/underserved treatment needs; regulatory reforms including an improved drug approval process; emergence of a superaged society requiring increasing healthcare and increasing budgetary costs; pressures on pricing as budgets continue to be overstretched; growth of foreign affiliated companies and the increasing number of mid-sized Japanese Pharma companies seeking global opportunities to offset the potential loss of domestic market share. Encompassing all of these trends is a volume-driven market with drug usage and drug utilization expected to continue to increase and to contribute to overall positive growth. The IMS Japan Pharmaceutical Market Review will highlight the key drivers, emerging trends and growth opportunities through 2015. Mr. Alan Thomas joined IMS in 1999. He has held various responsibilities during his time at IMS including roles in Client Services, Sales, and Marketing. In 2011, Alan was appointed Director Pharma Segmentation and Global Account Management. In this role he works with IMS teams globally to deliver expanded business intelligence and decision support to pharmaceutical companies in Japan and abroad. In addition, he supports IMS Thought Leadership and Market Insights initiatives in Japan. If you are interested in the pharmaceutical sector, you will not want to miss this event.